UK researchers have begun safety trials on a new TB vaccine in South Africa.
Oxford University and Welcome Trust researchers are leading the tests in the Western Cape area, where one in 100 infants suffers from TB.
Tuberculosis
Tuberculosis, caused by Mycobacterium tuberculosis, primarily affects the lung. It may spread to other organs.
Advertisement
The trials will reveal whether the injection given alongside the current BCG vaccine can protect people better from the disease than BCG alone.
"This vaccine is safe, and stimulates very high levels of the type of immune response we think we need to protect against TB," the BBC quoted Dr Helen McShane, the Oxford University and Wellcome Trust researcher leading the project, as saying.
![Tuberculosis in Children - Magnitude of the problem]( "Tuberculosis in Children - Magnitude of the problem")
In India nearly 3-4 million children have tuberculosis and another 94 million are at risk for this disease. The annual infection rate is about 3% and usual sources are adults.
"It is important for us to test whether or not this vaccine does work to stop people getting TB," she added.
The new vaccine has already passed safety trials in the Gambia, a country in Western Africa. The results of the trials suggest that the vaccine put a huge impact on how the body's immune system is primed to resist TB infection.
It works by stimulating immune system cells called T-cells to produce a stronger response to the BCG injection.
The researchers say if the vaccine proves to be safe, cheap and far more effective than BCG, with its effects lasting throughout life, then the reintroduction of universal immunisation in the UK "might be worthwhile".
Source: ANI
SRM/B
Tuberculosis in Children - Magnitude of the problem
In India nearly 3-4 million children have tuberculosis and another 94 million are at risk for this disease. The annual infection rate is about 3% and usual sources are adults.
Advertisement
"It is important for us to test whether or not this vaccine does work to stop people getting TB," she added.
The new vaccine has already passed safety trials in the Gambia, a country in Western Africa. The results of the trials suggest that the vaccine put a huge impact on how the body's immune system is primed to resist TB infection.
It works by stimulating immune system cells called T-cells to produce a stronger response to the BCG injection.
The researchers say if the vaccine proves to be safe, cheap and far more effective than BCG, with its effects lasting throughout life, then the reintroduction of universal immunisation in the UK "might be worthwhile".
Source: ANI
SRM/B
Sputum Test
Pulmonary tuberculosis is caused by Mycobacterium tuberculosis.It primarily involves lungs and extend to other parts of the body.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.